SciBase Secures First US Payer Coverage, Clearing Path for Scaled Dermatology Adoption

  • SciBase secured its first US payer coverage with a major insurance company on October 15, 2026, marking a critical milestone for reimbursement of its Nevisense technology.
  • The policy covers non-invasive skin assessments for melanoma evaluation under CPT code 0658T, expanding access for dermatology practices and patients.
  • SciBase aims to capture a significant share of the $1 billion market for skin cancer detection and skin barrier evaluation, targeting a 75% gross margin.
  • The company has already established commercial momentum in the US without broad private payer reimbursement, positioning it for scaled adoption.

SciBase's payer coverage breakthrough addresses a key constraint in US commercialization, enabling the conversion of clinical adoption into broader reimbursed utilization. This aligns with the growing demand for non-invasive diagnostics in dermatology, particularly as skin cancer rates rise and skin barrier health gains prominence. The company's recurring revenue model supports its high gross margin target, positioning it for sustainable growth in a $1 billion market.

Reimbursement Expansion
Whether SciBase can secure additional payer agreements to further scale Nevisense adoption in the US.
Market Penetration
The pace at which dermatology practices integrate Nevisense into standard care following reimbursement approval.
Global Ambitions
How SciBase leverages US success to accelerate its goal of becoming the global leader in non-invasive skin assessment.